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Objectives: Infants and children undergoing cardiopulmonary bypass for repair of
congenital heart defects are at substantial risk for excessive bleeding, contributing
greatly to morbidity and mortality. Aprotinin significantly reduces bleeding and
transfusion requirements in adults but is of indeterminate value for pediatric pa-
tients. The aim of this study was to determine plasma aprotinin concentrations in
these patients with a functional aprotinin assay.
Methods: Thirty patients less than 16 years of age scheduled for cardiac surgery
with aprotinin were enrolled. Aprotinin was administered as a 25,000 KIU/kg bolus,
35,000 KIU/kg cardiopulmonary bypass prime, and 12,500 KIU · kg1 · h1
continuous infusion. Blood samples for aprotinin concentrations (kallikrein-inhib-
iting units/milliliter) were obtained before aprotinin; 5 minutes post-bolus; 5 min-
utes after cardiopulmonary bypass initiation; 30 and 60 minutes on cardiopulmonary
bypass; on discontinuation of aprotinin; 1 hour after aprotinin discontinuation; and
4 hours after permanent separation from cardiopulmonary bypass. For analysis,
patients were grouped according to weight (10 kg, 10-20 kg,20 kg). Differences
between weight groups were assessed using an exact test for categoric variables and
1-way analysis of variance for continuous variables.
Results: Aprotinin concentrations differed significantly across weight groups. Five
minutes after aprotinin bolus and initiation of cardiopulmonary bypass, there was
significant correlation between weight and aprotinin concentration (r  .57, P 
.003; r  .69, P  .001, respectively).
Conclusion: A functional assay reveals significant variability in aprotinin concen-
tration for pediatric patients using current weight-based aprotinin dosing. Additional
investigation is necessary to determine target aprotinin concentration dosing regi-
mens to provide better efficacy.
Infants and children who undergo cardiopulmonary bypass (CPB) for repairof congenital heart defects are at substantial risk for excessive bleeding andtransfusion, contributing greatly to morbidity and mortality.1 Infants aged 1year or less bleed significantly more and receive more blood products thanchildren aged more than 1 year during the perioperative period.1 Twenty-four–hour blood loss may reach 110 mL/kg, and the median donor expo-
sure is 6 units for infants undergoing CPB.2 The cause of the excessive bleeding and
transfusion requirements is multifactorial. Hemodilution, preoperative platelet ag-
gregation abnormalities, complex operations with prolonged duration of CPB,
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severe hypothermia, and a significant inflammatory re-
sponse to CPB contribute in varying degrees to create
considerable hemostatic demand in these patients.3-5
Options for blood conservation are limited for infants
and children. Pharmacologic blood conservation measures,
such as antifibrinolytic agents, are popular because of the
ease of administration and availability. Aprotinin, a serine
protease inhibitor with anti-inflammatory and antifibrino-
lytic properties, significantly reduces bleeding and transfu-
sion requirements in adults who undergo CPB,6 but it is of
indeterminate value for pediatric patients.4,7-9 Possible ex-
planations include study design, empiric transfusion prac-
tices, and a wide range of aprotinin dosing regimens used as
indicated in Table 1. 5,7,9-12 More specifically, aprotinin
dosing regimens13 that do not achieve “target” aprotinin
concentrations14 believed necessary to inhibit plasmin ac-
tivity and fibrinolysis may be responsible for little or no
hemostatic benefit in some pediatric patients. Aprotinin
dosage for pediatric patients undergoing CPB has been
extrapolated from dosing regimens used for adults that have
not always proven efficacious.10,13 The paucity of proven
aprotinin dosing regimens in adults and pediatric patients
are partially related to the difficulty of determining aprotinin
concentrations to validate and modify previous or current
recommendations. Because severe allergic reaction, throm-
bosis, and renal dysfunction may occur with aprotinin, its
use may be unwarranted in certain high-risk infants and
children until efficacy is better established.
This study determines plasma aprotinin concentration
and assesses consistency with a functional aprotinin assay in
infants and children undergoing CPB who received aproti-
nin using a current weight-based approach.
Methods
After the protocol was approved by the institutional review board
approval and informed consent was obtained from a parent or
guardian, 30 patients less than 16 years of age scheduled to
undergo cardiac surgery with CPB and receive aprotinin were
enrolled. The decision to use aprotinin was determined by the
surgeon and anesthesiologist caring for the patient. A patient with
renal impairment associated with a serum creatinine greater than
2.5 mg/dL or allergy to aprotinin was excluded.
Anesthesia consisted of moderate-dose fentanyl (25-50 g/kg)
supplemented with midazolam, muscle relaxant, and volatile
agent. Standard monitoring for patients undergoing cardiac surgery
was used and included continuous arterial and central venous
pressure monitoring. Fluid administration was minimized before
the initiation of CPB. Anticoagulation was achieved with porcine
heparin (Elkins-Sinn Inc, Cherry Hill, NJ) administered in an
initial dose of 300 U/kg and followed by additional doses to
maintain a celite activated clotting time (ACT) of more than 750
seconds (Hemochron 800, International Technidyne Co, Edison,
NJ).
The extracorporeal circuit included a membrane oxygenator
(SCI-Med, Minneapolis, Minn). The circuit was primed with Plas-
malyte, calcium chloride, sodium bicarbonate 8.5%, mannitol
12.5%, and 250 mL of albumin 5%. If circulatory arrest or pro-
found hypothermia was anticipated, washed packed red blood cells
(PRBCs) were added to the priming volume to achieve a hemat-
ocrit (HCT) ranging from 18% to 23% on initiation of CPB. If the
temperature was to remain greater than 32°C, the HCT was kept at
more than 25%. Nonpulsatile flow during CPB was maintained at
2.2 L · min1 · m2. A nasopharyngeal temperature probe was
used for temperature monitoring. If circulatory arrest was used, 5
mg/kg of thiopental, 0.5 g/kg of mannitol 12.5%, and 0.5 mg/kg of
dexamethasone were given immediately before perfusion was in-
terrupted. On rewarming, the HCT was maintained at 21% to 25%.
Modified ultrafiltration (MUF) was performed for 15 minutes after
separation from CPB in patients weighing less than 20 kg. Patients
were enclosed with appropriate full body forced-air cover (Augus-
tine Medical, Inc, Eden Prairie, Minn) to maintain the temperature
during MUF. After MUF or separation from CPB, protamine,
0.013 mg/U of heparin, was given to neutralize heparin. Heparin
was considered adequately neutralized if the ACT was within 10%
of the pre-heparin baseline ACT value after protamine. Excessive
blood in the CPB circuit was returned to the patient or processed
as intraoperative autologous blood (IAB) with a Medtronic AT-
1000 (Medtronic Inc, Parker, Colo) to an HCT of 55%. Shed
mediastinal blood was not returned to the patient postoperatively.
All surgical procedures were performed by one of the coauthors
(F. J. P. or J. A. D.).
Allogeneic PRBCs were administered for a hemoglobin of 10
g/dL or less after separation from CPB. Non-red blood cell–
TABLE 1. Aprotinin dosing schedules
Author Year
Bolus
(KIU/kg)
Pump prime
(KIU/kg)
Continuous infusion
(KIU · kg1 · h1)
Dietrich et al10 1993 15,000 15,000 0
Dietrich et al10 1993 30,000 30,000 0
Boldt et al5 1993 25,000 25,000 25,000
Miller et al9 1998 20,000 20,000 10,000
Miller et al9 1998 40,000 40,000 20,000
Huang et al11 1993 50,000 600,000 KIU 5000
Mossinger and Dietrich12 1998 30,000 30,000 0
Boldt et al7 1993 20,000 20,000 20,000
Boldt et al7 1993 35,000 35,000 10,000
KIU, Kallikrein-inhibiting unit.
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containing blood products were given in response to evidence of
microvascular bleeding and these supporting laboratory studies:
thromboelastogram, platelet count, prothrombin time, activated
partial thromboplastin time, and fibrinogen concentration. In the
intensive care unit (ICU), blood products were given for excessive
mediastinal chest tube drainage and the previously mentioned
supporting laboratory studies.
Aprotinin was infused through a dedicated central venous cath-
eter. After a test dose, a 25,000 KIU/kg bolus, 35,000 KIU/kg
prime, and 12,500 KIU · kg1 · h1 continuous infusion of
aprotinin was administered. The infusion was discontinued 2 hours
after the patient’s arrival in the ICU. Participants had blood sam-
ples for plasma aprotinin concentrations (kallikrein-inhibiting
units per milliliter) obtained at these time intervals: before apro-
tinin (baseline); 5 minutes after the bolus; 5 minutes after initiation
of CPB; 30 and 60 minutes after initiation of CPB; on discontin-
uation of aprotinin; 1 hour after discontinuation of aprotinin; and
4 hours after permanent separation from CPB.
Each 800-L sample for aprotinin concentration was drawn
from an arterial catheter and placed in a tube with 100 L of
3.8% sodium citrate. Samples were immediately placed on ice
and separated into platelet-poor plasma and frozen at 70°C
until batch testing to determine the plasma aprotinin concen-
tration. The assay is based on the ability of aprotinin to inhibit
plasmin activity as the target enzyme as recently demonstrat-
ed.15,16 Plasma samples were diluted 50-fold with 0.3 mol/L
Tris-HCl, 0.15 mol/L NaCl, pH 7.3. Dilute plasma samples
were incubated with 10 L of 1 U/L added porcine plasmin
(Sigma P-8644, St Louis, Mo) for 30 minutes. Twenty micro-
liters of 1 mmol/L benzoyl-Phe-Val-Arg-p-nitroanilide (Sigma
B-7632) were added to the sample as a plasmin substrate, and
the spectrophotometric absorbance at 405 to 490 nm was read
for 10 minutes at 30-second intervals as an index of plasmin
activity. We calculated the amount of aprotinin in the sample
from a standard inhibition curve developed by adding known
concentrations of aprotinin to pooled citrated normal human
plasma (n  30, all male). Because the concentration of apro-
tinin added to the normal plasma in our standard inhibition
curve was measured in kallikrein-inhibiting units per milliliter,
we reported aprotinin concentration in kallikrein-inhibiting
units per milliliter. To measure aprotinin in the patient samples,
we defined the preoperative sample in the assay set as having
100% (uninhibited) plasmin activity and all other time points as
having a fraction of the zero time activity. Because the baseline
sample contained 0 KIU/mL aprotinin, the calculated aprotinin
concentration value of this sample was adjusted to zero, and an
identical adjustment was made to all the sample values of that
patient assayed on that day.
The mediastinal chest tube drainage was noted at 4 and 24
hours after arrival in the ICU for each patient. Variables recorded
include patient’s age, gender, height, weight, preoperative medi-
cations, heart defect, surgical procedure, anesthetic medications,
total heparin and protamine given, total amount of aprotinin re-
ceived, duration of CPB, aortic crossclamp and circulatory arrest,
minimal temperature, total fluids and transfusion requirements for
the intraoperative and initial 24-hour period in the ICU, duration of
intubation, and ICU stay.
Statistical Analysis
Because of staffing difficulties involving research personnel, 2 of
the 30 patients who enrolled preoperatively were not treated ac-
cording to protocol; consequently, only 28 patients are included in
this report. For analysis purposes, patients were grouped according
to weight (10 kg, 10-20 kg, 20 kg). Differences between
weight classifications were assessed using an exact test for cate-
goric variables and 1-way analysis of variance for continuous
variables. Pearson correlation analysis was performed to assess
whether patient age or weight was significantly correlated with
aprotinin concentration after the bolus or 5 minutes after initiation
of CPB. In all cases, 2-sided tests were used, with P values  .05
considered statistically significant.
Results
Demographic and surgical characteristics are presented in
Table 2 according to weight. Expressed as milliliters per
kilogram, the amount of intraoperative fluids did not differ
across weight groups except for the volume of colloid
administered during CPB in which heavier patients received
less milliliters per kilogram (P  .008). The CPB prime
volume (milliliters) and the aprotinin concentration of the
prime (kallikrein-inhibiting units per milliliter) increased
with weight (P  .002 and P  .001, respectively). The
operations are listed in Table 3. Two of the 13 patients
weighing more than 20 kg received the half Hammersmith
dose and 1 patient received the full Hammersmith dose of
aprotinin. These 3 patients each weighed more than 40 kg.
Aprotinin concentrations are displayed at 8 time intervals
in Figure 1. As illustrated in Figure 1, aprotinin concentra-
tions differed significantly across groups despite patients
receiving the same weight-based dose indicated earlier. Five
minutes after the bolus dose of aprotinin was administered,
there was a significant positive correlation between weight
and aprotinin concentration (r  .57, P  .003) (Figure 2).
Aprotinin concentration 5 minutes after the bolus dose was
also correlated with patient age (r  .44, P  .025). Five
minutes after initiation of CPB, there was a significant
positive correlation between weight and aprotinin concen-
tration (r  .69, P  .001) (Figure 3). Similarly, there was
a significant correlation between age and aprotinin concen-
tration (r .59, P .001) 5 minutes after initiation of CPB.
Perioperative transfusion requirements and blood loss are
summarized in Table 4. There was some evidence (P 
.066) indicating that 24-hour, but not 4-hour, blood loss
differs significantly according to weight. The amount of
intraoperative IAB and PRBC, expressed in milliliters per
kilogram, differed significantly according to weight with
heavier patients receiving more (P  .03) IAB and less (P
 .001) PRBC. The percentage of patients receiving fresh
frozen plasma intraoperatively also differed significantly (P
 .038) across weight groups with a higher percentage of
heavier patients receiving fresh frozen plasma. Postopera-
tive transfusion requirements did not differ significantly
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across weight groups. However, similar to the intraoperative
period, for the total perioperative period (intraoperative 
24 hours postoperative) the amount of IAB and PRBC
transfused and the percentage of patients exposed to fresh
frozen plasma differed significantly across weight groups
(Table 4). One patient, weighing more than 20 kg, required
mediastinal exploration for bleeding. There was no early
mortality.
Discussion
Aprotinin has been shown repeatedly to significantly reduce
bleeding and transfusion requirements in adults undergoing
CPB with a fixed-dose regimen since 1987.6,14 In contrast,
similar results in children undergoing CPB with aprotinin
have been indeterminate in neonates and infants even with
weight-based dosing regimens.7,8,13,17 Pediatric and adult
studies have rarely determined aprotinin concentrations to
validate or modify existing dosing regimens. Similar to
Dietrich and colleagues’ study,10 this study defines plasma
aprotinin concentrations in infants undergoing CPB but it
also includes children aged less than 16 years. The study
indicates that the failure of current pediatric aprotinin dos-
ing regimens to achieve target aprotinin concentrations is
partially a result of the difference in the volume of distri-
bution of aprotinin in infants compared with adults. Fur-
thermore, clearance of aprotinin and weight-based priming
dose are also important factors in the variability of aprotinin
concentrations with current dosing regimens.
Through application of our functional assay in patients
less than 16 years of age undergoing cardiac surgery with
CPB, large variations in aprotinin concentrations were iden-
tified at the 8 time periods examined with the current
investigation. Previously, Dietrich and colleagues10 charac-
terized plasma aprotinin concentrations only in infants with
congenital heart disease undergoing CPB. Forty infants
weighing less than 10 kg received either 30,000 KIU/kg or
60,000 KIU/kg of aprotinin intraoperatively as a bolus and
pump prime without incorporating a continuous infusion.
With similar sampling times in our investigation, peak apro-
tinin concentrations were only 99  25 KIU/mL for the
infants receiving the higher dose of aprotinin. These apro-
tinin concentrations are lower than the aprotinin concentra-
tions found in patients weighing less than 10 kg in our
study. Not surprisingly, the total amount of aprotinin and
dosage of aprotinin in our infants weighing less than 10 kg
(948,796  266,108 KIU) is considerably higher than that
found by Dietrich and colleagues10 (180,000  81,000
KIU). The significance of aprotinin concentrations centers
TABLE 2. Demographics and surgical characteristics (N  28)
Characteristics
<10 kg (n  9) 10–20 kg (n  6) >20 kg (n  13)*
P value†Mean  SD Mean  SD Mean  SD
Age, mo 7.8 3.6 60.2 13.7 136.7 39.6 .001
Gender, n (%) .127
Male 6 (67) 6 (100) 7 (54)
Female 3 (33) 0 (0) 6 (46)
Weight, kg 6.8 1.6 15.5 3.4 33.2 8.8 .001
Body surface area, m2 0.4 0.1 0.7 0.1 1.1 0.2 .001
Preoperative cyanosis, n (%) .885
No 5 (56) 4 (67) 6 (46)
Yes 4 (44) 2 (33) 7 (54)
Anesthesia duration, min 344 59 335 68 339 62 .964
Surgical time, min 219 37 247 29 254 55 .206
CPB time, min 84 23 80 21 86 33 .91
Crossclamp time, min 44 27 27 19 42 34 .553
CPB fluids
Crystalloid, mL/kg 135.6 97.1 94.6 48.7 94.4 60.1 .387
Colloid, mL/kg 26.4 20.7 12.0 9.9 6.9 6.3 .008
Intraoperative fluids
(excluding CPB)
Crystalloid, mL/kg 28.2 14.3 35.9 17.1 29.4 16.1 .631
Colloid, mL/kg 9.2 12.0 11.3 14.4 5.8 7.9 .578
Total, mL/kg 37.3 18.4 47.2 26.6 35.2 22.1 .553
CPB prime
Total volume, mL 905 155 1216 550 1605 457 .002
Aprotinin, KIU/mL 270.1 70.3 517.4 218.2 716.6 190.9 .001
CPB, Cardiopulmonary bypass.
*Two patients (46.7 and 41.8 kg) received a half dose of aprotinin and 1 patient (44.2 kg) received a full dose of aprotinin rather than the pediatric dosing
schedule.
†P values from Fisher’s exact test for categoric variables and 1-way analysis of variance for continuous variables.
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on the fact that in vitro plasma concentrations of aprotinin
have been related to antifibrinolytic and anti-inflammatory
activity at concentrations of 125 KIU/mL and 200 KIU/mL,
respectively.14 Although others have reported the antifi-
brinolytic activity of aprotinin to occur at a concentration as
low as 50 KIU/mL,18 it is certain that the anti-inflammatory
activity associated with kallikrein inhibition occurs at a
much higher plasma aprotinin concentration than antifibrin-
olysis. Notably, these “target” aprotinin concentrations are
not consistently achieved with current aprotinin weight-
based dosing regimens for infants and children.
Highly variable aprotinin concentrations have also re-
cently been reported in adults receiving aprotinin for cardiac
surgery requiring CPB.15,16 Beath and colleagues15 attrib-
uted fluctuations in aprotinin concentrations in their inves-
tigation in large part to the fixed amount of aprotinin ad-
ministered in accordance with the popularized
“Hammersmith” dose regimen.14 Consequently, the degree
of variability in aprotinin concentration despite weight-
based dosing in our pediatric subjects suggests other factors
to explain it. Foremost, hemodilution is recognized as more
pronounced in infants and smaller children than in adults
because priming volumes may exceed the infant’s blood
volume by as much as 400%. Dietrich and colleagues10 also
ascribed lower plasma aprotinin levels to the degree of
hemodilution associated with infants undergoing CPB. In
addition, the pharmacokinetics of infants and children vary
greatly from adults because of greater volume of distribu-
tions and liver or renal immaturity.19 These 2 factors, he-
modilution and pediatric pharmacokinetics, need to be con-
sidered in the formulation of an aprotinin dosing regimen
for infants and children who require cardiac surgery and
CPB.
In contrast with experiences of older children receiving
aprotinin,8 studies in neonates and infants have been at
variance regarding transfusion requirements and blood
loss.7 Our study reveals a strong positive relationship be-
tween weight and aprotinin concentration before (Figure 2)
and during (Figure 3) CPB. Accordingly, infants may not
attain aprotinin concentrations believed to confer anti-in-
flammatory or even antifibrinolytic activity, accounting for
some of the discrepancy between older and younger patients
regarding benefit. However, no investigation has proven
that a specific aprotinin concentration is associated with
reduced transfusion and bleeding in patients undergoing
CPB. Dietrich and colleagues10 correlated aprotinin concen-
tration with fibrin monomer levels, revealing lower fibrin
TABLE 3. Operative procedures*
<10 kg
(n  9)
10–20 kg
(n  6)
>20 kg
(n  13)
Aortic valve replacement 1
Bidirectional cavopulmonary
anastomosis
1 1
Central shunt 1
Complete AV canal repair 3 1
Complete repair of AV canal
with TOF
1 1
Fontan conversion 1
Modified Fontan 2 3
Pulmonary valve replacement 3
Replacement ascending
aorta
1
Resection of subaortic
stenosis
1
RV to PA conduit
replacement
2
RV outflow tract
reconstruction
3
Tricuspid valve repair 1
Tricuspid valve replacement 1
TAPVC complete repair 1
TOF with absent pulmonary
valve repair
1
TOF repair 2
VSD closure 1 1
AV, Atrioventricular; PA, pulmonary artery; RV, right ventricular; TOF,
tetralogy of Fallot; VSD, ventricular septal defect; TAPVC, total anomalous
pulmonary venous connection.
*Some patients received more than 1 procedure per operation.
Figure 1. Plasma aprotinin concentrations determined for each
patient at the following time intervals: (1) baseline (before apro-
tinin administration); (2) 5 minutes after aprotinin bolus; (3) 5
minutes after initiation of CPB; (4) 30 minutes during CPB; (5) 60
minutes during CPB; (6) discontinuation of aprotinin infusion; (7)
1 hour after aprotinin infusion was discontinued; and (8) 4 hours
after permanent separation from CPB. Aprotinin was adminis-
tered as a 25,000 KIU/kg bolus, 35,000 KIU/kg priming component,
and 12,500 KIU · kg1 · h1 continuous infusion. One patient
received full dose (280 mg bolus, 280 mg prime, and 70 mg/h
continuous infusion), and 2 patients received half dose (140 mg
bolus, 140 mg prime, and 35 mg/h continuous infusion). All of
these patients weighed more than 40 kg. *Significant difference
across weight groups (P < .05, 1-way analysis of variance). CPB,
Cardiopulmonary bypass; KIU, kallikrein-inhibiting unit.
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generation associated with a higher aprotinin concentration
that was also associated with significantly lower 6-hour
blood loss compared with patients who received lower dose
aprotinin. This indicates improved results with achievement
of higher blood concentrations of aprotinin.
Although our study was not powered to assess transfu-
sion and blood loss between infants and children as a
function of weight, overall there was a tendency for the
infants weighing less than 10 kg to bleed more postopera-
tively. It has been demonstrated that infants weighing less
than 8 kg and aged less than 1 month are more likely to
bleed excessively than older and heavier children.1,20 Al-
though red blood cell loss may be partially responsible for
PRBC transfusions, significant differences in intraoperative
allogeneic PRBCs identified in the study are likely the result
of greater hemodilution that accompanies infants undergo-
ing CPB. Beyond requiring more intraoperative PRBCs,
patients weighing less than 10 kg experienced greater 24-
hour mediastinal chest tube drainage than older patients in
accordance with the results of Miller and colleagues20 and
Williams and colleagues.1 Our study is unable to reach any
definitive conclusions about the relationship between blood
loss and transfusion and the marked variability of plasma
aprotinin concentrations in this pediatric population, al-
though it needs to be answered to fully assess future apro-
tinin dosing regimens.
Any attempt to develop recommendations for aprotinin
regarding infants and children undergoing CPB should in-
clude attainment of “target” aprotinin concentrations for
inhibition of fibrinolysis. Because of the marked systemic
inflammatory response that occurs as a result of CPB in
neonates and infants,21 inhibition of the inflammatory re-
sponse and fibrinolysis may be crucial. Our data indicate
that pediatric patients require dosing schedules that account
for their weights in relation to the size of the CPB circuits
and their pharmacokinetic differences. If the priming dose
of aprotinin is administered on the basis of a subject’s
weight alone, as is currently the practice, aprotinin concen-
trations will be significantly less than concentrations be-
lieved necessary to inhibit fibrinolysis and the inflammatory
response. As a result, we are developing a dosing regimen
for aprotinin that compensates for the apparent discrepancy
between the pediatric patient’s blood volume and the prim-
ing volume used for CPB to achieve aprotinin concentra-
tions in the range of 200 to 250 KIU/mL.
This study is limited in that we have determined plasma
aprotinin concentrations in a very heterogeneous patient
population with considerable pharmacokinetic variability
that may have distorted the relationship of aprotinin con-
centrations and certain weight relationships. In addition, the
number of patients weighing less than 10 kg was inadequate
to develop strong conclusions about this population. With-
out statistical power to assess differences in blood loss or
transfusion requirements in relation to aprotinin concentra-
tions, we are unable to comment about the importance of
attaining “target” aprotinin concentrations in this area. Fi-
nally, in contrast with our study, Dietrich and colleagues10
used a competitive enzyme-linked immunosorbent assay
(ELISA) as described by Muller-Esterl and colleagues22
rather than a functional assay for determination of plasma
aprotinin concentration. The validity of our functional assay
has been established in comparison with the ELISA-based
aprotinin concentrations with excellent correlation (r2 
0.94),15 but we did not perform any direct comparisons with
the ELISA in this study to further validate the correlation of
this functional assay. Recently, Cardigan and colleagues23
compared a functional aprotinin assay with ELISA in pa-
tients undergoing cardiac surgery. The correlation between
the 2 methods of measurement were excellent (r  .87), but
the functional assay was significantly higher than the
ELISA (234  104 KIU/mL vs 155  88 KIU/mL, respec-
tively, P  .0001). This indicates that the results obtained
with the different assays are not interchangeable. The ben-
efit of one assay compared with another cannot be deter-
Figure 2. Plasma aprotinin concentrations 5 minutes after the
bolus of aprotinin according to weight.
Figure 3. Plasma aprotinin concentrations 5 minutes after the
initiation of CPB according to weight.
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mined yet with regard to determining the most effective
dosing regimen for aprotinin use in cardiac surgery and
congenital heart repair.
Conclusion
A functional assay for aprotinin concentration reveals sig-
nificant variability in pediatric patients on the basis of
weight classifications despite current weight-based aproti-
nin dosing for CPB. The neonate and infant seem to be at
greater risk for subtherapeutic levels of aprotinin than the
older and heavier pediatric patient undergoing CPB primar-
ily because of priming volumes in excess of blood volume
and altered pharmacokinetics. Dosing regimens that achieve
“target” aprotinin concentrations for pediatric patients of all
weight groups need to be developed and evaluated for
impact on perioperative transfusion requirements and blood
loss. As a result, the role of aprotinin in blood conservation
strategy for pediatric patients undergoing cardiac surgery
and CPB will be better defined.
The authors thank Debra Kirtz for her secretarial assistance,
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the study.
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Transfused, % 22 17 46 .374
Fresh frozen plasma
mL/kg 0 0 0 2.8 6.8 0 1.5 3.1 .365
Transfused, % 0 17 23 .309
Platelets
mL/kg 0 0 0 1.1 2.6 0 1.3 3.1 .491
Transfused, % 0 17 15 .571
Total
IAB (mL/kg) 8.4 7.4 7.5 16.7 15.4 4.5 16.1 17.8 9.6 .022
Allogenic RBC
mL/kg 72.9 79.1 32.3 29.9 33.9 17.5 13.2 16.2 11.8 .001
Transfused, % 100 100 83 .487
Fresh frozen plasma
mL/kg 0 16.9 29.1 16.4 14.4 12.4 9.2 11.6 8.6 .805
Transfused, % 33 67 85 .047
Platelets
mL/kg 0 9.3 27.8 3.2 6.3 8.1 5.8 5.8 6.2 .888
Transfused, % 11 50 54 .125
Complications
Surgical reoperation within 24 h 0 (0) 0 (0) 1 (8) 1
ICU, Intensive care unit; MCTD, mediastinal chest tube drainage; RBC, red blood cell; IAB, intraoperative autologous blood.
*P values from Fisher’s exact test for categoric variables and 1-way analysis of variance for continuous variables.
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